IP Library Granted Patent US 12,097,223
Granted Patent B2
US 12,097,223 · App. 17/022,807 · Granted Sep 24, 2024

Mesenchymal stromal cells and uses related thereto

Inventors: Erin Anne Kimbrel (Sudbury, MA); Robert P. Lanza (Clinton, MA); Jianlin Chu (Bedford, MA); Nicholas Arthur Kouris (Hudson, MA)
Assignee: Astellas Institute for Regenerative Medicine
A61K35/28A61F2/141A61F9/08A61K35/30A61K35/34A61K35/36A61K35/39A61K35/407C12N5/0647C12N5/0662C12N5/0668C12N5/0692G06F9/542C12N2501/115C12N2501/125C12N2501/145C12N2501/155C12N2501/165C12N2501/26C12N2502/1171C12N2506/02C12N2506/11C12N2506/28C12N2533/54G06F2218/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,097,223
App. No.
17/022,807
Granted
Sep 24, 2024
Kind
B2
Abstract

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Claims (14)

1. A method for generating human mesenchymal stromal cells, the method comprising

(a) differentiating human pluripotent stem cells in vitro in a first medium comprising 20-100 ng/mL vascular endothelial growth factor (VEGF) and 15-100 ng/mL bone morphogenic protein 4 (BMP-4) to generate cell clusters,

(b) culturing the cell clusters in a second medium comprising 20-100 ng/mL VEGF, 15-100 ng/mL BMP-4, and 20-25 ng/mL basic fibroblast growth factor (bFGF),

(c) dissociating the cell clusters to obtain single cells,

(d) culturing the single cells in a serum free, methylcellulose-based medium to generate hemangioblasts, and

(e) differentiating the hemangioblasts in vitro to generate human mesenchymal stromal cells, wherein said hemangioblasts are cultured in the presence of transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), insulin-like growth factor 1, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), or a combination thereof.

2. The method of claim 1 , wherein step (e) comprises culturing said hemangioblasts in feeder-free conditions or on a matrix.

3. The method of claim 2 , wherein said hemangioblasts are cultured in the presence of transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), insulin-like growth factor 1, basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF).

4. The method of claim 2 , wherein said hemangioblasts are cultured on a matrix and said matrix comprises laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, heparan sulfate, a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, a human basement membrane extract, or any combination thereof.

5. The method of claim 1 , wherein the second medium further comprises stem cell factor (SCF), Flt 3L (FL), thrombopoietin (TPO), or tPTD-HOXB4.

6. The method of claim 1 , wherein the serum free, methylcellulose-based medium comprises one or more of insulin, transferrin, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), bone morphogenic protein 4 (BMP-4), and tPTD-HOXB4.

7. The method of claim 1 , wherein the human pluripotent stem cells comprise embryonic stem cells or induced pluripotent stem cells.

8. The method of claim 1 , wherein the human mesenchymal stromal cells are isolated at passage 2 (p2).

9. The method of claim 1 , wherein the single cells are cultured in (d) at a concentration of 1-1.5×10 6 cells/mL.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: KIMBREL, ERIN ANNE; LANZA, ROBERT; CHU, JIANLIN; KOURIS, NICHOLAS ARTHUR
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 055700/0455 →
CHANGE OF NAME Recorded Mar 24, 2021
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 055701/0403 →
CHANGE OF NAME Recorded Mar 24, 2021
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 055701/0410 →
Cited By (2)
US 12,419,958 US 12,465,621